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Perspective: In 2004, the DINAMIT trial reported that
ICDs did not improve survival in patients with an acute MI
6-40 days earlier. The present study confirms this finding in
a similar patient population. Interestingly, in both studies,
the ICD group had fewer arrhythmic or sudden deaths, but
more nonarrhythmic deaths than the control group, perhaps
because the ICD allowed high-risk patients to survive a fatal
arrhythmia only to eventually die from pump failure.
Summary written by: Fred Morady, MD 
Congenital Heart Disease
Long-Term Results of Catheter-Based Treatment of
Pulmonary Atresia and Intact Ventricular Septum
Marasini M, Gorrieri PF, Tuo G, et al.
Heart 2009;95:1520–1524.
Study Design: What are the outcomes of patients with pul-
monary atresia with intact ventricular septum (PAIVS) after
interventional perforation of the pulmonary valve? 
Methods: A retrospective review of neonates with PAIVS was
performed at a single center. Exclusion criteria included right
ventricular dependent coronary circulation, hypoplastic
monopartite right ventricle, and severe Ebstein anomaly of the
tricuspid valve.
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Arrhythmias
Defibrillator Implantation Early After Myocardial
Infarction
Steinbeck G, Andresen D, Seidl K, et al., on behalf of the IRIS
Investigators.
N Engl J Med 2009;361:1427–1436.
Study Design: Do implantable cardioverter defibrillators
(ICDs) improve survival when implanted in high-risk
patients within 1 month of a myocardial infarction (MI)? 
Methods: In this study, 898 patients (mean age 77 years) with
an MI within 5-31 days, ejection fraction ≤40%, and resting
heart rate ≥90 bpm or nonsustained ventricular tachycardia
received an ICD (n = 445) or only medical therapy (n =
453). Patients were followed at 3- to 6-month intervals. 
Results: Mean follow-up was 37 months. There was no sig-
nificant difference in all-cause mortality between the ICD
and medical groups at 1 year (10.6% vs. 12.5%, respectively),
2 years (15.4% vs. 18.2%), or 3 years (22.4% vs. 22.9%). The
risk of sudden cardiac death was 45% lower in the ICD
group, but was counterbalanced by a 92% increase in non-
sudden cardiac death in the ICD group.
Conclusions: Prophylactic ICDs do not improve survival when
implanted in high-risk patients shortly after an acute MI.
Results: There was a low incidence of silent (2.7%) and clinical
(4.1%) MI in this cohort; 36.8% of all MIs were silent. Being
male, older age, longer diabetes duration, prior cardiovascular
disease (CVD), neuropathy, higher glycated hemoglobin,
albuminuria, high serum creatinine, and insulin use all signif-
icantly predicted risk of clinical or silent MI. Fenofibrate
reduced MI by 19%, nonfatal clinical MI by 24%, and silent
MI by 16%. Among those having silent MI, fenofibrate
reduced subsequent clinical CVD events by 78%. 
Conclusions: Silent and clinical MI have similar risk factors
and increase the risk of future CVD events. Fenofibrate
reduces the risk of a first MI and substantially reduces the
risk of further clinical CVD events after silent MI, support-
ing its use in type 2 diabetes.
Perspective: The initial report of the FIELD trial was disap-
pointing. While fenofibrate reduced microvascular disease
and nonfatal MI, there was no reduction in total or CV
mortality. Although the findings regarding silent MI are
robust, it would not be appropriate to add fenofibrate to
standard treatment of diabetics with the expectation of low-
ering risk of silent and subsequent MI. However, the report
provides support for adding fenofibrate to statins in diabetes
when non–high-density lipoprotein is not at target, and in
statin-intolerant patients. 
Summary written by: Melvyn Rubenfire, MD
Heart Failure/Transplant
Use of Aldosterone Antagonists in Heart Failure
Albert NM, Yancy CW, Liang L, et al.
JAMA 2009;302:1658–1665.
Study Design: How often are aldosterone antagonists pre-
scribed based on heart failure (HF) management guideline
criteria and investigator-defined appropriateness criteria, and
what are the trends in patients hospitalized with HF?
Methods: A total of 43,625 patients admitted with HF and
discharged home from 241 hospitals participating in the Get
With The Guidelines–HF quality improvement registry
between January 2005 and December 2007 were analyzed.
The main outcome measures were prescription and predic-
tors of use of aldosterone antagonists, based on guideline
criteria.
Results: Among 12,565 patients eligible for aldosterone
antagonist therapy, 32.5% (n = 4,087) received an aldos-
terone antagonist at discharge. Treatment increased
modestly from 28% to 34% over the study period, with wide
variation in use among hospitals (0%-90.6%). Utilization
Results: Over 14 years, 40 patients underwent radiofrequency
perforation. The procedure was successful in 39 patients.
Perforation of the infundibulum occurred in two patients.
Overall mortality was 7.5%, with two early and one late
death. Median follow-up was 6.49 years; 19 patients
required no further intervention. Four patients underwent a
bidirectional Glenn procedure. The remainder underwent
surgical two-ventricular repair. Patients who died or needed
additional interventions had a higher incidence of bipartite
right ventricle (65% vs. 15.8%, p = 0.0004), and a lower
median tricuspid valve z-score (-2, range -3.5 to 1 vs. -0.5,
range -2 to 1, p = 0.004).
Conclusions: Percutaneous interventional perforation is an
effective first-stage procedure for PAIVS.
Perspective: PAIVS is a heterogeneous anatomic lesion with
many variations in management strategies. The procedural
success rate in this study was high, with a low complication
rate. One attractive aspect is that for ~50% of the patients,
this was the only intervention required. Further study is
required to understand which patients are the best candi-
dates for particular approaches.
Summary written by: Timothy B. Cotts, MD 
General Cardiology
Incidence and Predictors of Silent Myocardial
Infarction in Type 2 Diabetes and the Effect of
Fenofibrate: An Analysis From the Fenofibrate
Intervention and Event Lowering in Diabetes
(FIELD) Study
Burgess DC, Hunt D, LiPing L, et al.
Eur Heart J 2009;Sep 29:[Epub ahead of print].
Study Design: What is the effect of fenofibrate on silent
myocardial infarction (MI) in a large cohort of patients with
type 2 diabetes?
Methods: The FIELD study was conducted in 9,795 patients
with type 2 diabetes, ages 50-75 years, who were random-
ized to fenofibrate 200 mg daily or matching placebo.
Patients were excluded if they had had a clinical myocardial
infarction (MI) within 3 months before study entry.
Physicians were allowed to add other cholesterol-lowering
medications if indicated. Clinical events and safety out-
comes were monitored every 4-6 months over an average 
5 years of follow-up. Routine electrocardiograms were
assessed for presence of new Q waves without clinical 
presentation.
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ence in either the secondary endpoint (p = 0.31), or rate of
major bleeding between the two strategies. Hospital stay
was shorter (median 55 vs. 77 hours) with an immediate
intervention strategy.
Conclusions: An immediate intervention strategy is feasible
and safe in patients with NSTEMI-ACS, but does not pro-
vide any advantage over a strategy of next working day
intervention.
Perspective: An early invasive strategy is considered optimal
for treating patients with NSTEMI-ACS, although how
early to treat has not been clearly defined. The results of this
trial echo the TIMACS study, where there was no advantage
of early over late catheterization to prevent death, MI, or
stroke at 6-month follow-up. The totality of evidence sug-
gests that a strategy of timing angiography as early as
logistically feasible provides the best outcome with respect to
safety and resource utilization.  
Summary written by: Hitinder S. Gurm, MD    
Dual Antiplatelet Therapy for More Than 12 Months
After Percutaneous Coronary Intervention: Insights
From the Guthrie PCI Registry 
Harjai KJ, Shenoy C, Orshaw P, Boura J.
Heart 2009;95:1579–1586. 
Study Question: Is there a benefit of continuing dual
antiplatelet (DAP) therapy for longer than 1 year after a
percutaneous coronary intervention (PCI)?
Methods: This was a single-center observational study of 1,859
patients who underwent successful PCI of a native coronary
artery and survived event-free for at least 12 months. The
treating physician determined duration of DAP. 
Results: A total of 835 patients were treated with bare-metal
stents and 1,024 with drug-eluting stents. Average duration
of DAP was 27 months in patients treated beyond 12
months and 4.1 months in those treated for less than 1 year.
At a median follow-up of 3.4 years after PCI, there was no
difference in outcome for patients treated for >1 or <1 year
(death or myocardial infarction [MI], 9.4% vs. 10.3%).
Longer treatment was not independently associated with a
reduction in death or MI (p = 0.95). Analysis restricted to
patients treated with bare-metal stents, drug-eluting stents,
or those with acute MI, diabetes, or American College of
Cardiology/American Heart Association type C lesions
showed similar results.
Conclusions: Continuation of DAP beyond 1 year does not
appear to impart any clinical benefit in patients undergoing
stent-based PCI.
was more likely when the patients were younger, African
American, and had lower systolic blood pressure, history of
implantable cardioverter defibrillator use, depression, alco-
hol use, pacemaker implantation, and no history of renal
insufficiency. After applying serum creatinine and potassium
appropriateness criteria, inappropriate use of aldosterone
antagonist therapy was low and did not change over the
study period.
Conclusions: Less than one-third of eligible patients hospital-
ized for HF and participating in a quality improvement
registry received HF guideline–recommended aldosterone
antagonist therapy, and utilization among patients with doc-
umented contraindications was low.
Perspective: The findings of this study are of concern because
this lifesaving therapy is not being considered in eligible HF
patients. Based on the results of several studies including the
RALES trial, aldosterone antagonists should be used in eligi-
ble HF patients without waiting for a Joint Commission on
Accreditation of Healthcare Organizations mandate. As the
benefits of polypharmacy are accompanied by increased risk,
HF therapy is best managed by a dedicated comprehensive HF
management program when available. 
Summary written by: Ragavendra R. Baliga, MBBS
Interventional Cardiology
Immediate vs Delayed Intervention for Acute
Coronary Syndromes: A Randomized Clinical Trial
Montalescot G, Cayla G, Collet JP, et al., on behalf of the ABOARD
Investigators.
JAMA 2009;302:947–954. 
Study Question: Is immediate intervention on admission better
than delayed intervention in patients with non–ST-elevation
acute coronary syndrome (NSTEMI-ACS)?
Methods: The ABOARD study randomized 352 patients
with NSTEMI-ACS and a Thrombolysis in Myocardial
Infarction (TIMI) score of 3 or more to receive intervention
either immediately or on the next working day. The primary
endpoint was the peak troponin value during hospitalization,
and secondary was the composite of death, MI, or urgent
revascularization at 1-month follow-up. 
Results: Time from presentation to sheath insertion was 70
minutes in the immediate intervention and 21 hours in the
delayed therapy arm. There was no difference in the primary
endpoint between the two strategies (median troponin I
value, 2.1 ng/ml in the immediate vs. 1.7 ng/ml in the
delayed intervention group, p = 0.70). There was no differ-
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Perspective: The optimal duration of DAP after PCI remains
debatable. Although one study suggested a reduction in
hard events with longer duration of DAP (JAMA
2007;297:159–68), this and other studies (Am J Cardiol
2008;102:1017–22 ) have not found evidence to support the
need for prolonged DAP. Thus, prolonged DAP should be
restricted to select patients where the benefits are expected
to outweigh the risks and cost.  
Summary written by: Hitinder S. Gurm, MD
Noninvasive Cardiology
Independent Value of Left Atrial Volume Index for
the Prediction of Mortality in Patients With
Suspected Heart Failure Referred From the
Community
Lim TK, Dwivedi G, Hayat S, Majumdar S, Senior R.
Heart 2009;95:1172–1178.
Study Question: Is there independent power of left atrial vol-
ume index (LAVI) to predict mortality in patients with
suspected heart failure (HF) referred from the community?
Methods: A cohort of 356 patients, ages 72 ± 13 years, with
suspected HF referred from the community were followed up
for mortality after undergoing clinical assessment, electrocar-
diogram (ECG) and echocardiography, including Doppler, to
assess left ventricular (LV) filling.
Results: Data were obtained for 335 (94%) patients (162
male, 173 female) over a mean follow-up of 30 ± 10
months, during which 38 ± 11.3% died. Univariate predic-
tors of all-cause mortality included age, symptom of leg
swelling, clinical signs of HF, abnormal ECG, LV ejection
fraction, LAVI, LV end-systolic and end-diastolic dimen-
sion, septal wall thickness, and presence of any other
significant cardiac abnormality on echocardiography. The
only independent predictors of mortality were age (p <
0.001), symptom of leg swelling (p = 0.005), LAVI (p =
0.04), and LV end-systolic dimension (p = 0.04). 
Conclusions: LAVI provided information independent of
clinical and other echocardiographic variables for predicting
mortality in patients referred from the community with sus-
pected HF.
Perspective: Congestive HF carries an adverse prognosis,
including HF with impaired LV systolic function, HF with
normal LV ejection fraction, and HF due to underlying heart
valve disease. This study suggests that one crude measure of
LV filling pressure, LAVI >20 ml/m2, had prognostic power
in predicting mortality among patients with suspected HF. It
makes intuitive sense that LA enlargement, as a nonspecific
marker of high LV diastolic pressure due to any cause, is a
marker of adverse prognosis.  
Summary written by: David S. Bach, MD 
Multislice Computed Tomography Coronary
Angiography for Risk Stratification in Patients With
an Intermediate Pretest Likelihood
van Werkhoven JM, Gaemperli O, Schuijf JD, et al.
Heart 2009;95:1607–1611.
Study Question: Is multislice CT coronary angiography useful
for risk stratification of patients suspected of coronary artery
disease (CAD)?
Methods: Multislice CT images were assessed for significant
CAD in patients with intermediate pretest likelihood of
CAD, defined as a pretest likelihood between 13.4% and
87.2%. Criteria that categorized patients by factors such as
gender and symptoms were used. In addition, patients with
diabetes were considered intermediate risk and were included.
The primary endpoint was a composite endpoint of all-cause
mortality, nonfatal infarction, and unstable angina requiring
revascularization. Mean follow-up was 621 days.
Results: A total of 316 patients were analyzed (60% male,
mean age 57 years), including 26 patients lost to follow-up
and 21 who underwent early revascularization. Significant
CAD was observed in 89 (28%) patients. During follow-up,
13 patients experienced a primary event (1% had a nonfatal
myocardial infarction, 2% had unstable angina requiring
revascularization, and 2% died). The annualized event rate
was 0.8% in patients with a normal CT coronary angiogra-
phy, 2.2% in those with nonsignificant CAD, and 6.5% for
those with significant CAD, both by CT coronary angiogra-
phy. CT angiography findings remained a significant
predictor of events in multivariate analysis. 
Conclusions: Among patients with a pretest likelihood of
CAD, CT coronary angiography was useful for the predic-
tion of those who are at risk for further events.
Perspective: These findings support the use of CT angiogra-
phy for risk stratification; however, although noninvasive,
CT imaging exposes patients to radiation. Therefore, this
risk needs to be discussed with patients prior to imaging.
Further investigation regarding the re-classification of
patients in terms of risk is warranted to understand the use-
fulness of such testing.  
Summary written by: Elizabeth A. Jackson, MD 
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Prevention/Vascular
C-Reactive Protein as a Risk Factor for Coronary
Heart Disease: A Systematic Review and Meta-
Analyses for the U.S. Preventive Services Task
Force
Buckley DI, Fu R, Freeman M, Rogers K, Helfand M.
Ann Intern Med 2009;151:483–495.
Study Question: C-reactive protein (CRP) may help refine
global risk assessment for coronary heart disease (CHD),
particularly among persons at intermediate risk based on
traditional risk factors alone. Should CRP be incorporated
into guidelines for CHD risk assessment?
Methods: The authors used MEDLINE (1966 to November
2007), supplemented by reviews, pertinent studies, editori-
als, Web sites, and expert suggestions. Studies were limited
to prospective cohort, case-cohort, and nested case-control
studies relevant to the independent predictive ability of CRP
in intermediate-risk persons. Included studies were reviewed
according to predefined criteria, and the quality of each
study was rated. The validity of the body of evidence and
the net benefit or harm of using CRP for CHD risk assess-
ment were evaluated. The combined magnitude of effect
was determined by meta-analysis. All studies utilized high-
sensitivity CRP.  
Results: Twenty-three articles represented the most pertinent
publication for meta-analysis from each of 24 cohort studies.
One study included patients with CHD, and adjusted for
prevalent CHD. The body of evidence is of good quality,
consistency, and applicability. For good studies that adjusted
for all Framingham risk variables, the summary estimate of
relative risk for incident CHD was 1.58 (95% confidence
interval, 1.37-1.83) for CRP levels greater than 3.0 mg/L
compared with levels less than 1.0 mg/L. Analyses from
four large cohorts found evidence that including CRP
improves risk stratification among initially intermediate-risk
persons. CRP has desirable test characteristics, and good
data exist on the prevalence of elevated CRP levels in inter-
mediate-risk persons. Limited evidence links changes in
CRP level to primary prevention of CHD events.
Conclusions: Strong evidence indicates that CRP is associated
with CHD events. Moderate, consistent evidence suggests
that adding CRP to risk prediction models among initially
intermediate-risk persons improves risk stratification.
However, sufficient evidence that reducing CRP levels pre-
vents CHD events is lacking.
Perspective: There is literature to support that high-sensitivity
CRP is not an independent risk marker, but rather a reflection
Complementary Prognostic Values of Stress
Myocardial Perfusion and Late Gadolinium
Enhancement Imaging by Cardiac Magnetic
Resonance in Patients With Known or Suspected
Coronary Artery Disease
Steel K, Broderick R, Gandla V, et al.
Circulation 2009;120:1390–1400.
Study Question: What are the prognostic implications of
reversible perfusion defect (RevPD) with cardiac magnetic
resonance (CMR) myocardial perfusion imaging (MPI), and
late gadolinium enhancement (LGE) imaging for adverse
cardiac events during follow-up?
Methods: The authors performed CMR MPI followed by
LGE imaging on 254 patients with symptoms of myocardial
ischemia. To determine whether RevPD and LGE could
provide complementary prognostic association with major
adverse cardiac events, they built a model that included
patient age, gender, and left ventricular (LV) systolic func-
tion and then entered both RevPD and LGE into the
model.  
Results: At a median follow-up of 17 months, 49 cardiac
events occurred, including 12 cardiac deaths, 16 acute
myocardial infarctions (MIs), and 21 cardiac hospitaliza-
tions. RevPD and LGE both maintained a >3-fold
association with cardiac death or acute MI when adjusted for
each other and for the effects of patient age and gender. In
patients without a history of MI who had negative RevPD,
LGE presence was associated with a >11-fold hazard
increase in death/MI. Patients with neither RevPD nor
LGE had a 98.1% negative annual event rate for death/MI.
For association with major adverse cardiac events, RevPD
was the strongest multivariable variable in the best overall
model (p < 0.0001).
Conclusions: Characterization of RevPD and LGE by CMR
provides strong and complementary prognostic implications
for cardiac death or acute MI.
Perspective: Prevalence of CAD in the study cohort was high
compared with other contemporary studies. Additional
studies will need to be performed to determine whether the
results may be extrapolated to the same degree in a popula-
tion with substantially lower CAD prevalence. The current
study also does not provide information on the relative clin-
ical value of CMR compared to computed tomography
angiography or nuclear imaging for the evaluation of
patients with symptoms of cardiac ischemia.  
Summary written by: Debabrata Mukherjee, MD    
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of the major risk factors; that the ability to further assign risk
to an individual patient does not warrant the cost; that it may
have some value in further risk stratifying the intermediate-
risk group; and that it has value in further risk stratifying even
low-risk men >50 years and women >60 years of age. My bias
is that it is helpful to characterize relative risk and number
needed to treat, albeit not an individual’s risk.  
Summary written by: Melvyn Rubenfire, MD    
Emerging Risk Factors for Coronary Heart Disease:
A Summary of Systematic Reviews Conducted for
the U.S. Preventive Services Task Force
Helfand M, Buckley DI, Freeman M, et al.
Ann Intern Med 2009;151:496–507.
Study Question: Traditional risk factors do not explain all of
the risk for incident coronary heart disease (CHD) events.
What is the evidence of value of new or emerging risk fac-
tors for improving global risk assessment for CHD?
Methods: The authors performed a MEDLINE search for
English-language articles published from 1966 to September
2008, using the terms “cohort studies” and “cardiovascular dis-
eases” in combination with terms for each risk factor. Studies
were included if the participants had no baseline cardiovascu-
lar disease, follow-up for at least 2 years, and the investigators
adjusted for at least five of the seven Framingham risk factors.
Study quality was evaluated by using the U.S. Preventive
Services Task Force criteria and a modified version of the
Grading of Recommendations, Assessment, Development,
and Evaluation framework.
Results: Nine systematic reviews were conducted. C-reactive
protein (CRP) was the best candidate for use in screening and
the most rigorously studied, but evidence that changes in
CRP level lead to primary prevention of CHD events is
inconclusive. The other evaluated risk factors were coronary
artery calcium score as measured by electron-beam computed
tomography, lipoprotein(a) level, homocysteine level, leuko-
cyte count, fasting blood glucose, periodontal disease,
ankle-brachial index, and carotid intima-media thickness. The
availability and validity of the evidence varied considerably
across the risk factors in terms of aggregate quality, consis-
tency of findings, and applicability to intermediate-risk
persons in the general population.
Conclusions: Current evidence does not support routine use of
any of the nine risk factors for further risk stratification of
intermediate-risk persons.
Perspective: The U.S. Preventive Services Task Force strongly
recommends screening lipids in men >35 years and women
>45 years old or from age 20 years and older in those consid-
ered at increased risk for CHD, as well as screening for
hypertension at age ≥18 years. These and other recommenda-
tions, as well as the conclusions regarding the ‘nine risk
factors,’ are reasonable. But in light of the MESA study,
equating the utility of identifying preclinical vascular disease
by coronary artery calcification with plasma analyses for pre-
dicting outcome, infers a total lack of appreciation of the
results.  
Summary written by: Melvyn Rubenfire, MD 
Using Nontraditional Risk Factors in Coronary
Heart Disease Risk Assessment: U.S. Preventive
Services Task Force Recommendation Statement
U.S. Preventive Services Task Force.
Ann Intern Med 2009;151:474–482.
Study Question: Are nontraditional risk factors recommended in
screening for coronary heart disease (CHD)?
Methods: Systematic literature reviews were conducted with
publications dating from 1996 to present on nine nontradi-
tional markers of CHD risk, including high-sensitivity
C-reactive protein (CRP), ankle-brachial index, leukocyte
count, fasting blood glucose, periodontal disease, carotid
intima media thickness, coronary artery calcification scores on
electron beam computed tomography (CT) scan, homocys-
teine, and lipoprotein(a). The aim of the review was to
determine which factors would reassign persons deemed
intermediate risk (by Framingham score) into either a high-
or low-risk category.
Results: Overall for each nontraditional risk factor, insufficient
evidence was available, thus additional risk factor assessment
could not be recommended. The task force discussed the fol-
lowing related findings. For CRP, an estimated 11% of men
with an intermediate risk would be reclassified into a high-risk
category, while an estimated 12% would be reclassified into a
low-risk stratum. Evidence suggests that lipoprotein(a) levels
predict events after adjustment for other risk factors; however,
no studies used Framingham risk scores, or examined reclassi-
fication of risk categories using lipoprotein(a). Four of seven
studies found leukocyte counts were independently predictive
of CHD. Fasting glucose appears to be a weak predictor of
CHD in nondiabetics. CRP was the only risk factor in which
sufficient evidence allowed for estimation of magnitude of
benefit; however, it was still uncertain given the lack of data
regarding the overall risk related to intensive therapy and
potential harms of testing.
Conclusions: Current evidence was not sufficient to assess the
balance between benefit and harm of these nontraditional risk
factors in screening asymptomatic men and women with no
history of CHD.
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Perspective: The task force’s clinical guidelines regarding use of
nontraditional risk factors for CHD risk assessment are
thought-provoking and should be recommended reading for
providers interested in prevention. Understanding the need for
risk-benefit data related to risk factors and the concerns
regarding adverse side effects of risk factor categorization and
management is critical to the safe and effective use of all risk
factor measures.  
Summary written by: Elizabeth A. Jackson, MD  
A Randomized Study on the Effect of Weight Loss
on Obstructive Sleep Apnea Among Obese Patients
With Type 2 Diabetes: The Sleep AHEAD Study
Foster GD, Borradaile KE, Sanders MH, et al., on behalf of the Sleep
AHEAD Research Group of the Look AHEAD Research Group.
Arch Intern Med 2009;169:1619–1626.
Study Question: What is the effect of weight loss on obstructive
sleep apnea (OSA) over a 1-year period in diabetics?
Methods: The Sleep AHEAD (Action for Health in Diabetes)
study is an ancillary investigation of OSA within the Look
AHEAD study, a 16-center randomized, controlled clinical
trial investigating the long-term health impact of an intensive
lifestyle intervention. Sleep AHEAD enrolled 264 patients
with OSA from the total cohort of 304 patients in four cen-
ters. Participants were randomly assigned to either a
behavioral weight loss program developed for obese patients
with type 2 diabetes (intensive lifestyle intervention [ILI]) or
three group sessions related to effective diabetes management
(diabetes support and education [DSE]).
Results: The mean age was 61.2 years; weight was 102.4 kg,
body mass index was 36.7 kg/m2, and apnea-hypopnea index
(AHI) was 23.2 events per hour. ILI participants lost more
weight at 1 year than DSE participants (10.8 kg vs. 0.6 kg; 
p < 0.001). ILI intervention was associated with an adjusted
decrease in AHI of 9.7 events per hour (p < 0.001). At 1 year,
more than 3 times as many participants in the ILI group had
total remission of OSA, and prevalence of severe OSA among
ILI participants was half that of the DSE group. Initial AHI
and weight loss were the strongest predictors of changes in
AHI at 1 year (p < 0.01). Participants with a weight loss of 10
kg or more had the greatest reductions in AHI.
Conclusions: Physicians and their patients can expect that
weight loss will result in significant and clinically relevant
improvements in OSA among obese patients with type 2
diabetes.
Perspective: The impressive results demonstrate two important
points. First, weight loss is possible and, if achieved, can have
a benefit on OSA, a serious cardiac risk factor. But sadly, the
diabetic education and support groups lost only 0.6 kg. A
much more aggressive and hands-on effort is necessary. In
this study, for example, the intensive lifestyle change group
included portion-controlled diets, with 30% or less calories
from fat. The physical activity prescription was 175 minute/
week of moderate-intensity activity such as brisk walking.  
Summary written by: Melvyn Rubenfire, MD 
Adherence to Antihypertensive Medications and
Cardiovascular Morbidity Among Newly Diagnosed
Hypertensive Patients
Mazzaglia G, Ambrosioni E, Alacqua M, et al. 
Circulation 2009;120:1598–1605.
Study Question: What are the predictors of adherence to antihy-
pertensive treatment and the association of adherence with
acute cardiovascular events?
Methods: Using data from 400 Italian primary care physicians
in the Health Search/Thales Database, the authors selected
18,806 newly diagnosed hypertensive patients ≥35 years of
age during 2000-2001. Subjects were newly treated for
hypertension and initially free of cardiovascular diseases.
Patient adherence was subdivided a priori into three cate-
gories—high (proportion of days covered, ≥80%),
intermediate (40-79%), and low (≤40%)—and compared with
the long-term occurrence of acute cardiovascular events
through the use of multivariable models adjusted for demo-
graphic factors, comorbidities, and concomitant drug use.
Results: Mean age at entry was 62 years, 41.6% were male,
and 27.5% had at least one cardiovascular risk factor. At
baseline (i.e., 6 months after index diagnosis), 8.1%, 40.5%,
and 51.4% of patients were classified as having high, inter-
mediate, and low adherence levels, respectively. Multiple
drug treatment, dyslipidemia, diabetes mellitus, obesity, and
antihypertensive combination therapy were significantly (p <
0.001) associated with high adherence to antihypertensive
treatment. Only high adherers had a significantly decreased
risk of acute cardiovascular events (p = 0.032).
Conclusions: The long-term reduction of acute cardiovascular
events associated with high adherence to antihypertensive
treatment underscores its importance in assessing beneficial
effects of evidence-based therapies. An effort focused on early
antihypertensive treatment initiation and adherence is likely
to provide major benefits.
Perspective: Its likely adherence is influenced by patients’ per-
ception of overall risk, as influenced by comorbidities and
need for other treatments such as statins. Nevertheless, the
literature is clear that treating relatively low-risk patients with
only mild hypertension can reduce vascular events. It is
important that physicians emphasize the need for lifestyle
change with diet and exercise, and continued use of medica-
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tion as necessary depending on lifelong home blood pressure
tracking.  
Summary written by: Melvyn Rubenfire, MD
Three-Year Efficacy of Complex Insulin Regimens in
Type 2 Diabetes
Holman RR, Farmer AJ, Davies MJ, et al., for the 4-T Study Group.
N Engl J Med 2009;361:1736–1747.
Study Question: What is the relative value of specific insulin reg-
imens superimposed on oral therapy in patients with type 2
diabetes mellitus?
Methods: A 3-year open-label multicenter trial was conducted
in 708 patients 18 years or older (insulin naïve) with subop-
timal glycated hemoglobin (HbA1c) levels (range 7-10%)
while taking metformin and sulfonylurea therapy. Patients
were randomly assigned to receive one of three regimens: 1)
twice daily biphasic insulin aspart (70/30), 2) prandial
insulin aspart (short-acting) 3x daily, or 3) basal insulin
detemir (a once nightly insulin). Sulfonylurea therapy was
replaced by a second insulin for hyperglycemia. Target
preprandial glucose levels were 72-90 mg/dl, and 2-hour
postprandial 90-126 mg/dl. Hypoglycemia was defined as
symptoms and a self-measured glucose <56 mg/dl. Outcome
measures were HbA1c levels, the percentage with an HbA1c
<6.5%, rate of hypoglycemia, and weight gain. 
Results: Mean age was 61.7 years. The proportion who with-
drew was significantly different, ranging from 5.1% for twice
daily biphasic insulin to 11.7% for 3x daily, and 8.5% once
nightly. At 1 year, median HbA1c was similar, ranging from
6.8% for 3x prandial to biphasic 7.1%. However, fewer had a
level of <6.5% in the biphasic (31.9%) than the 3x prandial
(44.7%) or basal groups (43.3%), with >67% of each group
needing a second insulin. Median per patient/year rates of
hypoglycemia were lowest in the basal nightly group (1.7) and
highest in the prandial group (5.7) (p < 0.001). Mean weight
gain was highest in the prandial group. 
Conclusions: Patients who added a basal or prandial insulin-
based regimen to oral therapy had better HbA1c control than
those who added a biphasic-insulin-based regimen. Fewer
hypoglycemic episodes and less weight gain occurred in
patients adding basal insulin.
Perspective: Adding insulin to oral therapy is no small chal-
lenge if the target HbA1c is <7%. Study participants are
usually well motivated, and in this study, over 67% in each
group were willing to add a second insulin. Much less hypo-
glycemia (which increases morbidity and mortality) provides
support for single-dose insulin regimen.  
Summary written by: Melvyn Rubenfire, MD 
Prevention/Vascular
Vardenafil Treatment for Patients With Pulmonary
Arterial Hypertension: A Multicentre, Open-Label
Study
Jing ZC, Jiang X, Wu BX, et al.
Heart 2009;95:1531–1536.
Study Question: What are the long-term effects of vardenafil,
a phosphodiesterase-5 (PDE-5) inhibitor, in patients with
pulmonary arterial hypertension (PAH)?
Methods: A multicenter, open-label study of 1-year duration
was undertaken in 45 patients with PAH (stable World
Health Organization [WHO] functional class II-IV) in five
Chinese centers. The primary purpose was to determine the
long-term safety and efficacy of vardenafil (5 mg once daily
for the first 4 weeks, then 5 mg twice daily). The patients’
clinical features, exercise capacity, WHO functional class,
and hemodynamic variables were measured at baseline and at
3 and at least 9 months after initiating vardenafil treatment. 
Results: Thirty-six women and nine men had a mean age of
32.5 years. Diagnoses were idiopathic PAH in 10. In 35
patients, PAH was associated with connective tissue disease
in 11, congenital heart disease in 23, and portopulmonary
hypertension in one patient. Vardenafil was given for a
mean of 14 months. At the 3-month and a mean of 14-
month follow-up assessments, 6-minute walk distance was
significantly increased from baseline by 70.7 m (p < 0.001)
and 83.4 m (p < 0.001), respectively. Long-term treatment
with vardenafil (mean >1 year) was also associated with
improvements in hemodynamic parameters, WHO func-
tional class, and serum uric acid concentrations.
Conclusions: Long-term treatment with vardenafil is well toler-
ated and has sustained beneficial effects on PAH, as
measured by patients’ exercise capacity, WHO functional
class, and hemodynamic parameters.
Perspective: The FDA approved PDE-5 inhibitors are sil-
denafil and tadalafil, each of which has undergone extensive
placebo-controlled trials. Previous studies of vardenafil were
not promising, and it has not undergone such trials. These
results are quite impressive and might be enough to encour-
age the manufacturer to study vardenafil further, but should
not be used for deciding which, if any, PDE-5 inhibitor is
warranted at present.  
Summary written by: Melvyn Rubenfire, MD 
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